Companies › Helixon Biotechnology (Suzhou)
2 active drug programs in 2 registered trials: 2 Phase 1; Other; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| HXN6005 | – | Phase 1 | Healthy Volunteers (HV) | Mar 2027 |
| HX15001 | – | Phase 1 | Healthy Volunteers | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06999720 | HX15001 | Phase 1 | Healthy Volunteers | Other | Sep 2026 |
| NCT07449741 | HXN6005 | Phase 1 | Healthy Volunteers (HV) | Other | Mar 2027 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.